SAMHSA recognizes the challenges posed by the current COVID-19 situation and is providing the following guidance and resources to assist individuals, providers, communities, and states across the country. SAMHSA stands ready to assist in any manner possible. SAMHSA Resources and Information Synar letter to the State Authority for Mental and Substance Use Disorders (PDF | 389 KB) Leveraging Existing Health and Disease Management Programs to Provide Mental Health and Substance Use Disorder Resources During the COVID-19 Public Health Emergency (PHE) (PDF | 73 KB) COVID-19 Emergency Response for Suicide Prevention Grants CLOSED Double Jeopardy: COVID-19 and Behavioral Health Disparities for Black and Latino Communities in the U.S. (PDF | 427 KB) Guidance for Law Enforcement and First Responders Administering Naloxone (PDF | 117 KB) Letter to Treatment Providers on PPE (PDF | 543 KB) SAMHSA COVID-19 Funded Grants (PDF | 340 KB) Intimate Partner Violence and Child Abuse Considerations During COVID-19 (PDF | 328 KB) Emergency Grants to Address Mental and Substance Use Disorders During COVID-19 CLOSED COVID-19 Information for SAMHSA Discretionary Grant Recipients COVID-19 Public Health Emergency Response and 42 CFR Part 2 Guidance (PDF | 168 KB) TAP 34: Disaster Planning Handbook for Behavioral Health Treatment Programs Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic (PDF | 125 KB) Considerations for Crisis Centers and Clinicians in Managing the Treatment of Alcohol or Benzodiazepine Withdrawal during the COVID-19 Epidemic: March 19, 2020 (PDF | 213 KB) Considerations for Outpatient Mental and Substance Use Disorder Treatment Settings (PDF | 104 KB) COVID-19: Interim Considerations for State Psychiatric Hospitals (PDF | 210 KB) UPDATED: Training and Technical Assistance Related to COVID-19 (PDF | 230 KB) Virtual Recovery Resources (PDF | 244 KB) Tips For Social Distancing, Quarantine, And Isolation During An Infectious Disease Outbreak Disaster Distress Helpline Telework and DFWP Drug Testing During COVID-19 Guidance for OTPs Opioid Treatment Program (OTP) Guidance (March 16, 2020) (PDF | 216 KB) OTP Guidance for Patients Quarantined at Home with the Coronavirus (PDF | 160 KB) FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency (PDF | 202 KB) Sample OTP COVID-19 FAQs (PDF | 341 KB) Use of Telemedicine While Providing Medication-Assisted Treatment (PDF | 146 KB) Additional Federal Guidance NEW: FCC Eases Lifeline Enrollment Process To Qualifying Low-Income Consumers During Covid-19 Pandemic (Deadline: June 20) Information on the program and how to apply Find Lifeline carriers in your area Trumpov Administration Issues Second Round of Sweeping Changes to Support U.S. Healthcare System During COVID-19 Pandemic DEA SAMHSA Buprenorphine Telemedicine (PDF | 209 KB) OCR Announces Notification of Enforcement Discretion for Telehealth Remote Communications During the COVID-19 Nationwide Public Health Emergency The Notification of Enforcement Discretion on Telehealth Remote Communications DEA Information on Telemedicine (PDF | 75 KB) DEA Diversion Control Division COVID-19 Information Stay up to Date Coronavirus.gov Coronavirus Disease 2019 (COVID-19) What the U.S. Government is Doing